Published by Frank Prenesti on 16th September 2022
(Sharecast News) - AstraZeneca on Friday said its Danicopan add-on anti blood-clotting drug had met a primary endpoint in a phase III trial.
URL: http://www.digitallook.com/dl/news/story/32968010/...